Novo Nordisk A/S : Reduction of the share capital

20 March 2014, it was decided to reduce the company's B share capital from DKK
442,512,800 to DKK 422,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 100,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 20,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 530,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 422,512,800.
The reduction in the share capital will not affect Novo Nordisk's share repurchase
programme which will continue as previously announced.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B

shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 25 / 2014

Page 2 of 2

Lars Borup Jacobsen

Daniel Bohsen

Jannick Lindegaard (US)

+45 3075 3479

+45 3079 6376

+l 609 235 8567

lbpj@novonord isk.com dabo@ novonordisk.com j lis@ novonordisk.com

Novo Nordisk A/S

Investor Relations

Navo Allé

2880 Bagsvcerd

Denmark

Te leph on e:

+45 4444 8888

Internet:

www. n ovo n o rdi s k. co m

CVR no:

24 25 67 90

Compa ny a nn ouncement N o 25 l 2014

distributed by